SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q3 Trading Update

5 Nov 2015 07:00

RNS Number : 6149E
Rentokil Initial PLC
05 November 2015
 



  

RENTOKIL INITIAL PLC (RTO)

THIRD QUARTER (Q3) TRADING UPDATE

5 November 2015

 

Results

Q3 2015

Growth

YTD 2015

Growth

£m

AER

AER

CER

AER

AER

CER

Revenue

438.0

(0.4%)

4.1%

1,293.3

-

4.3%

Revenue - ongoing operations1

436.2

0.3%

4.8%

1,287.2

0.7%

5.1%

 

 

Overview (CER)Revenue from ongoing operations increased by 4.8% in the quarter. Q3 organic revenue growth was in line with the second quarter at 1.4% with 3.4% growth from acquisitions. Growth in the Emerging (+11.1%) and Growth (+9.3%) quadrants was strong, with revenue in the Protect and Enhance (-1.4%) and Manage for Value (-4.7%) quadrants down on last year. Revenue from ongoing operations for the nine months ended 30 September 2015 ("year-to-date") increased by 5.1% with organic growth of 1.7% and 3.4% from acquisitions.

Performance continues to be strong in the UK, North America, Asia, Pacific and Latin America driven by continued strong growth in pest control. While conditions remain difficult in France and the Netherlands, year-to-date ongoing revenue in the Europe region is in line with last year.

Cash flowYear-to-date operating and free cash flow are ahead of the prior year and we are confident of delivering free cash flow for the year in excess of £100m.

M&AIn Q3 we acquired five businesses, all in pest control in our Emerging and Growth quadrants. Combined annual revenues of the businesses acquired totalled £17m in the 12 months immediately prior to acquisition. Year-to-date we have acquired 19 businesses with combined annual revenues of £38m. As previously announced our acquisition of The Steritech Group Inc completed on 2nd October and the process of integration is underway and on track.

Commenting on trading in Q3, Andy Ransom, CEO of Rentokil Initial plc, said:"We continue to execute our strategy at pace with the recent acquisition of Steritech providing us with a high quality business with national scale in a key growth market. The performance in the majority of the group continues to be strong although trading in Europe, France in particular, remains challenging. Our guidance for the full year is unchanged."

 

 

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

01276 536585 / 07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978 199

John Sunnucks

Bell Pottinger

0203 772 2549

 

 

 

AER - actual exchange rates; CER - constant 2014 exchange rates

 

1ongoing revenue excludes the financial performance of disposed and closed businesses but includes results from acquisitions

 

This announcement contains statements that are, or may be, forward-looking regarding the group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKMMGMNDRGKZM
Date   Source Headline
28th Jul 20253:00 pmRNSHolding(s) in Company
10th Jul 202511:00 amRNSHolding(s) in Company
1st Jul 202510:25 amRNSTotal Voting Rights
10th Jun 202510:05 amRNSAdditional Listing
3rd Jun 20254:00 pmRNSDirector/PDMR Shareholding
28th May 20257:00 amRNSSale of France Workwear
19th May 20252:30 pmRNSDirector/PDMR Shareholding
7th May 20254:15 pmRNSResult of AGM
7th May 20257:01 amRNSDirectorate Change: Appointment of NEDs
7th May 20257:00 amRNSDirectorate Change: Chief Executive to retire
28th Apr 20252:30 pmRNSIssue of Debt
17th Apr 20252:20 pmRNSHolding(s) in Company
17th Apr 20257:00 amRNSQ1 Trading Update
9th Apr 202510:25 amRNSHolding(s) in Company
1st Apr 20252:15 pmRNSNotice of Q1 Trading Update and Management Call
1st Apr 202510:25 amRNSBlock listing Interim Review
27th Mar 202510:25 amRNSDirector/PDMR Shareholding
26th Mar 202510:30 amRNSAnnual Financial Report
14th Mar 202510:00 amRNSDirector/PDMR Shareholding
6th Mar 20257:00 amRNSFinal Results
28th Jan 20257:00 amRNSTrading Update (unaudited)
14th Jan 202511:15 amRNSHolding(s) in Company
13th Jan 202511:15 amRNSHolding(s) in Company
13th Dec 20249:30 amRNSDirector/PDMR Shareholding
25th Nov 20247:00 amRNSDirectorate Change
12th Nov 202410:30 amRNSHolding(s) in Company
8th Nov 202410:30 amRNSHolding(s) in Company
17th Oct 20247:00 amRNSQ3 Trading Update
1st Oct 20242:00 pmRNSBlock listing Interim Review
25th Sep 20247:00 amRNSAppointment of Non-Executive Director
19th Sep 202410:30 amRNSDirector/PDMR Shareholding
11th Sep 20247:00 amRNSTrading Update
10th Sep 202410:30 amRNSHolding(s) in Company
5th Sep 202411:08 amRNSHolding(s) in Company
25th Jul 20247:00 amRNS2024 Interim Results
10th Jul 20244:35 pmRNSHolding(s) in Company
26th Jun 20245:12 pmRNSDirector/PDMR Shareholding
26th Jun 202411:08 amRNSHolding(s) in Company
17th May 20243:30 pmRNSDirector/PDMR Shareholding
8th May 20242:00 pmRNSResult of AGM
29th Apr 20243:00 pmRNSHolding(s) in Company
23rd Apr 20249:30 amRNSHolding(s) in Company
18th Apr 20247:00 amRNSQ1 Trading Update
2nd Apr 20241:28 pmRNSBlock listing Interim Review
2nd Apr 202412:17 pmRNSTotal Voting Rights
27th Mar 202410:23 amRNSAnnual Financial Report
19th Mar 20242:05 pmRNSAdditional Listing
14th Mar 202410:19 amRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSFinal Results
1st Dec 20237:00 amRNSNorth American Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.